Susquehanna International Group, LLP Arcturus Therapeutics Holdings Inc. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 38,768 shares of ARCT stock, worth $621,063. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,768

Previous 48,610 20.25%

Holding current value

$621,063

Previous $1.18 Million 24.01%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$18.08 - $25.38 $177,943 - $249,789	-9,842 Reduced 20.25%	38,768 $899,000
Q2 2024 Aug 15, 2024	BUY	$24.35 - $44.39 $661,906 - $1.21 Million	27,183 Added 126.86%	48,610 $1.18 Million
Q1 2024 May 07, 2024	SELL	$31.23 - $42.99 $2.08 Million - $2.87 Million	-66,762 Reduced 75.7%	21,427 $723,000
Q4 2023 Feb 14, 2024	BUY	$17.71 - $32.97 $564,523 - $1.05 Million	31,876 Added 56.61%	88,189 $2.78 Million
Q3 2023 Nov 14, 2023	SELL	$25.44 - $37.35 $3.13 Million - $4.6 Million	-123,180 Reduced 68.63%	56,313 $1.44 Million
Q2 2023 Aug 11, 2023	BUY	$23.94 - $32.36 $2.99 Million - $4.05 Million	125,091 Added 229.94%	179,493 $5.15 Million
Q1 2023 May 16, 2023	SELL	$14.72 - $23.97 $40,715 - $66,301	-2,766 Reduced 4.84%	54,402 $1.3 Million
Q4 2022 Feb 14, 2023	SELL	$14.14 - $23.06 $930,115 - $1.52 Million	-65,779 Reduced 53.5%	57,168 $969,000
Q3 2022 Nov 14, 2022	SELL	$13.05 - $22.13 $231,702 - $392,918	-17,755 Reduced 12.62%	122,947 $1.82 Million
Q2 2022 Aug 15, 2022	BUY	$12.26 - $31.17 $125,052 - $317,934	10,200 Added 7.82%	140,702 $2.22 Million
Q1 2022 May 16, 2022	SELL	$17.64 - $39.57 $1.24 Million - $2.78 Million	-70,292 Reduced 35.01%	130,502 $3.52 Million
Q4 2021 Feb 14, 2022	BUY	$34.2 - $47.56 $1.95 Million - $2.71 Million	57,022 Added 39.66%	200,794 $7.43 Million
Q3 2021 Nov 15, 2021	BUY	$27.88 - $58.25 $971,339 - $2.03 Million	34,840 Added 31.98%	143,772 $6.87 Million
Q2 2021 Aug 11, 2021	BUY	$25.79 - $42.11 $1.85 Million - $3.02 Million	71,702 Added 192.59%	108,932 $3.69 Million
Q1 2021 May 17, 2021	SELL	$38.75 - $86.92 $4.9 Million - $11 Million	-126,531 Reduced 77.27%	37,230 $1.54 Million
Q4 2020 Feb 16, 2021	SELL	$34.61 - $123.66 $1.1 Million - $3.93 Million	-31,754 Reduced 16.24%	163,761 $7.1 Million
Q3 2020 Nov 16, 2020	BUY	$37.49 - $63.19 $3.64 Million - $6.13 Million	97,053 Added 98.57%	195,515 $8.39 Million
Q2 2020 Aug 14, 2020	SELL	$12.66 - $58.27 $394,903 - $1.82 Million	-31,193 Reduced 24.06%	98,462 $4.6 Million
Q1 2020 May 15, 2020	BUY	$9.31 - $18.26 $376,738 - $738,909	40,466 Added 45.37%	129,655 $1.76 Million
Q4 2019 Feb 14, 2020	SELL	$8.93 - $12.41 $19,387 - $26,942	-2,171 Reduced 2.38%	89,189 $969,000
Q3 2019 Nov 14, 2019	BUY	$8.8 - $14.5 $441,821 - $728,001	50,207 Added 122.0%	91,360 $938,000
Q2 2019 Nov 14, 2019	BUY	$5.78 - $9.79 $237,864 - $402,887	41,153 New	41,153 $388,000

Others Institutions Holding ARCT

# of Institutions

180

Shares Held

25.7M

Call Options Held

195K

Put Options Held

133K

View Full List

About Arcturus Therapeutics Holdings Inc.

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $426M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

More about ARCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Arcturus Therapeutics Holdings Inc. Transaction History